Biolinq, a San Diego, CA-based digital health company, closed a $10M Series A financing.
The round was led by M Ventures, with participation from Hikma Ventures, Grey Sky Venture Partners, Three Leaf Ventures, LifeSci Venture Partners and a group of high-net-worth individuals specialized in the diabetes field. In conjunction with the funding, Edward Kliphuis, Investment Director of the New Businesses fund at M Ventures, and Lana Ghanem, Managing Director of Hikma Ventures, will be joining the Board of Directors.
The company intends to use the funds to accelerate growth of its technology platform.
Founded in 2012 (as Electrozyme, LLC) and led by Jared Tangney, CEO, Biolinq is a digital health company with a wirelessly-enabled biosensor patch capable of continuously monitoring multiple biomarkers. Its first commercial product, a minimally-invasive technology device will allow patients with diabetes to continuously monitor their blood glucose without the pain and hassle of traditional continuous glucose monitoring (CGM) systems.
Experienced life science executive Dan Bradbury, the former CEO of Amylin Pharmaceuticals, has joined as executive chairman.